[{"id":"d2b6223e-ea5a-495b-b8a6-af55be3af32d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410145","created_at":"2022-06-08T12:57:49.059Z","updated_at":"2024-07-02T16:34:27.196Z","phase":"Phase 1/2","brief_title":"A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","source_id_and_acronym":"NCT05410145","lead_sponsor":"D3 Bio (Wuxi) Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed • elisrasib (D3S-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-06-11"}]